Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.

[1]  J. Spertus,et al.  Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study , 2015, European journal of preventive cardiology.

[2]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[3]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[4]  J. Spertus,et al.  Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). , 2013, Journal of the American College of Cardiology.

[5]  R. Wender,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[6]  Marc Evans,et al.  Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes , 2013, The Journal of clinical endocrinology and metabolism.

[7]  Harshal R. Patil,et al.  Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. , 2012, The American journal of cardiology.

[8]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[9]  F. Gueyffier,et al.  Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials , 2012, PLoS medicine.

[10]  A. Vaag,et al.  Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. , 2011, European heart journal.

[11]  L. Rydén,et al.  Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study , 2011, Diabetologia.

[12]  R. Heine,et al.  Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study , 2010, The Lancet.

[13]  Darren K Mcguire,et al.  Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs , 2009, Current cardiology reports.

[14]  E. Braunwald,et al.  Economic Impact of Angina After an Acute Coronary Syndrome: Insights From the MERLIN-TIMI 36 Trial , 2009, Circulation. Cardiovascular quality and outcomes.

[15]  C. Mogensen,et al.  Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. , 2008, Diabetes research and clinical practice.

[16]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[17]  R. Nesto,et al.  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.

[18]  K. Wolski,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[19]  I. Konstantinov,et al.  Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. , 2007, American journal of physiology. Heart and circulatory physiology.

[20]  R. Brook,et al.  Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population , 2002, Heart.

[21]  J R Hampton,et al.  Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population , 1999, Heart.

[22]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[23]  G. Knatterud,et al.  Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. , 1971, JAMA.

[24]  J. Spertus,et al.  Bmc Cardiovascular Disorders the Impact of Diabetes on One-year Health Status Outcomes following Acute Coronary Syndromes , 2022 .